The competition regulator has warned that if Tabcorp is allowed to go ahead with its $11 billion merger with Tatts it will create a gaming behemoth that will dominate the market.
“Tabcorp would become, by a very significant margin, the dominant provider of wagering in Australia,” counsel for the Australian Competition & Consumer Commission, Andrew McClelland, QC, told a tribunal hearing in Melbourne yesterday.
Hearings before the Australian Competition Tribunal to decide the fate of the proposed deal began yesterday as Tim Pallas, Treasurer for the State of Victoria weighed into the debate, pleading with any merged entity to remain in Victoria and continue to grow.
“We are proud to have had Tabcorp headquartered in Melbourne for many years. The company has made a significant contribution to this state,” he said.
The ACCC also returned fire at Tabcorp’s attack on the regulator as “not connected to reality”, saying in written submissions that “the assertion by Tabcorp that the ACCC has engaged in speculative theories of harm is pejorative and without foundation”.
Full Content: Financial Review
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan